热门资讯> 正文
艾伯维的Elahere在加拿大获得卵巢癌批准
2025-09-03 02:01
- Health Canada has approved AbbVie's (NYSE:ABBV) antibody-drug conjugate Elahere (mirvetuximab soravtansine) for ovarian cancer.
- The treatment is approved for women who have received one to three other therapies.
- More specifically, Elahere is approved for folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
- Elahere was given priority review and its approval was supported by data from the MIRASOL phase 3 trial.
- It is given every three weeks as an intravenous infusion.
More on AbbVie
- AbbVie Smashes Earnings, Bets Big On Depression Drug Bretisilocin
- AbbVie: Plenty Of Positives
- AbbVie Is A Top Biotech Pick
- Key deals this week: Hawkins, Canada Goose, AbbVie, Verint and more
- J&J halts studies for potential rival to AbbVie’s Humira after trial setback
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
